New drug cocktail aims to stop rare liver cancer from coming back
NCT ID NCT07243951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining an immunotherapy drug (cadonilimab) with a chemotherapy pill (capecitabine) can prevent a rare mixed liver cancer from returning after surgery. About 75 adults who had their tumor completely removed but are at medium-to-high risk of recurrence will receive the combo for up to 6 months. Researchers will measure how long patients stay cancer-free and track side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple belly press make liver cancer radiation more precise?
- Can a Heat-and-Freeze treatment plus a vaccine outsmart pancreatic cancer?
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure
- Can a cancer vaccine prime the body to better fight liver tumors?
- A drug used during liver surgery may cut the risk of major complications — a study puts it to the test
- Engineered immune cells take aim at childhood liver cancers